This page shows the latest ASH 2019 news and features for those working in and with pharma, biotech and healthcare.
In the phase 3 CARDINAL study reported at the ASH congress this week, sutimlimab given as an intravenous infusion on day zero and day seven – followed by biweekly dosing – achieved the ... 11th December 2019.
During a presentation of the results at the annual ASH 2019 conference, Andrew Wei, from the Alfred Hospital and Monash University, Melbourne, Australia, said: “ Based on the results of the QUAZAR ... 11th December 2019.
Regeneron also presented data for its candidate in multiple myeloma at ASH, which demonstrated a 75% response rate in the higher dosed group. ... 10th December 2019.
The much anticipated first results from the first two dose groups in the phase 1/2 trial of REGN5458 were presented at ASH 2019. ... 10th December 2019.
Updated results presented at ASH 2019. Sangamo has been playing catch-up with BioMarin in the race to develop a gene therapy for haemophilia A, but new data reported at the ... ASH 2019 congress suggest Pfizer-partnered SB-525 could gain ground.
The impressive data – presented at ASH 2019 – showed that Calquence (acalabrutinib) combined with Roche’s Gazyva(obinutuzumab) significantly improved progression-free survival (PFS) when compared to standard chemo-immunotherapy treatment.
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...